Citadel Advisors’s Liminal BioSciences Inc. Common Shares LMNL Stock Holding History

Citadel Advisors’s Portfolio LMNL Stock Details LMNL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,617	Closed	-$13K	–	13970
2022 Q2	$13K	Buy	+2,617	New	+$17K	﹤0.01%	12532
2021 Q4	–	Sell	-3,754	Closed	-$56.3K	–	15119
2021 Q3	$86K	Sell	3,754 -1,070	-22%	-$30.8K	﹤0.01%	13013
2021 Q2	$188K	Buy	+4,824	New	+$210K	﹤0.01%	12229
2021 Q1	–	Sell	-1,220	Closed	-$51K	–	13883
2020 Q4	$51K	Buy	+1,220	New	+$66.8K	﹤0.01%	10564
2020 Q3	–	Sell	-1,130	Closed	-$118K	–	10952
2020 Q2	$118K	Buy	+1,130	New	+$99.9K	﹤0.01%	8899

Other funds holding LMNL

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ECM

Estabrook Capital Management New York $685M AUM 26.64% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Citadel Advisors's LMNL Position: Q3 2022 in Review

Citadel Advisors sold out of Liminal BioSciences Inc. Common Shares (LMNL) in Q3 2022, closing a stake of 2,617 shares — an estimated $13K sold.

Citadel Advisors first reported a position in LMNL in Q2 2020 and held it in 5 quarters. The position peaked at $188K in Q2 2021. 15 funds tracked by Wall St. Rank hold LMNL as of Q3 2022.

Citadel Advisors reported no remaining Liminal BioSciences Inc. Common Shares position as of Q3 2022 after selling out during the quarter.
Citadel Advisors sold 2,617 Liminal BioSciences Inc. Common Shares shares in Q3 2022, an estimated $13K.
Citadel Advisors first reported a position in Liminal BioSciences Inc. Common Shares in Q2 2020 and held it in 5 quarters.
Citadel Advisors's Liminal BioSciences Inc. Common Shares position peaked at $188K in Q2 2021.
15 funds tracked by Wall St. Rank held Liminal BioSciences Inc. Common Shares as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.